ETS1-activated SNHG10 exerts oncogenic functions in glioma via targeting miR-532-3p/FBXL19 axis
- PDF / 11,454,589 Bytes
- 16 Pages / 595.276 x 790.866 pts Page_size
- 117 Downloads / 184 Views
Cancer Cell International Open Access
PRIMARY RESEARCH
ETS1‑activated SNHG10 exerts oncogenic functions in glioma via targeting miR‑532‑3p/ FBXL19 axis Lide Jin†, Shengquan Huang†, Congjin Guan* and Shun Chang*
Abstract Background: In past few years, long non-coding RNAs (lncRNAs) have been reported to play regulatory roles during cancer progression. LncRNA SNHG10 has been explored in several sorts of cancers. However, its detailed role and mechanism are still not well understood in glioma. Methods: Expression levels of genes were evaluated by RT-qPCR. EdU, TUNEL, sphere formation, wound healing and transwell assays appraised the effect of SNHG10 on glioma cellular processes. The interaction between molecules was examined by ChIP, RIP, RNA pull down and luciferase reporter assays. Results: High level of SNHG10 was detected in glioma cells. Functional assay confirmed that SNHG10 promoted the proliferation, migration, invasion and stemness of glioma cells. Moreover, miR-532-3p was validated to bind with SNHG10 and expressed at a low level in glioma cells. Importantly, miR-532-3p exerted inhibitory functions in glioma. Furthermore, it was found that FBXL19 targeted by miR-532-3p facilitated cell growth and stemness in glioma, and that SNHG10 worked in glioma by increasing FBXL19 expression through sequestering miR-532-3p. More importantly, ETS1 promoted the transcription of SNHG10 and it mediated contribution to the malignant behaviors of glioma cells by SNHG10/miR-532-3p/FBXL19 signaling. Conclusion: SNHG10 was transcriptionally activated by ETS1 and played an oncogenic role in glioma by sponging miR-532-3p and up-regulating FBXL19. Keywords: SNHG10, miR-532-3p, FBXL19, Glioma, ETS1 Background Glioma is considered as one of the most common tumors occurring in human brain and occupies around 80% of total brain tumors [1, 2]. According to recent reports, glioma could be classified into four grades according to malignancy and lesion location [3]. The invasive characteristic of high-grade glioma determines that there is no distinctive boundary between glioma and normal brain *Correspondence: [email protected]; [email protected] † Lide Jin and Shengquan Huang co-first authors The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming 650032, Yunnan, China
tissue [4, 5]. Moreover, the current radiotherapy and chemotherapy had limited therapeutic effects on glioma [6, 7]. Hence, it is necessary to find more efficient biomarkers for improving the treatment of glioma patients. In recent years, attentions have been increasingly attached into target therapy due to the advance of scientific technology and biology. Long non-coding RNAs (lncRNAs) are identified to play crucial roles in the development of cancers [8]. Numerous lncRNAs are demonstrated to have potential values in treating tumors [9]. LncRNA PLAC2 reduced the expression of RPL36 and repressed cell cycle progression in glioma by targeting STAT1 [10]. LncRNA H19 was up-r
Data Loading...
